drugset / Trial / NCT00752466
A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately
Phase 1
Completed
75 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Jan-Cil Italy · collabJan-Cil Spain · collabJan-Cil Switzerland · collabJan-Cil UK · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this open-label study is to determine if concomitant therapy with topiramate and flunarizine has any effect on the pharmacokinetics of either drug. Safety will be assessed for all subjects, for the entire duration of the study.
Timeline
- Start
- 2003-03
- Primary completion
- —
- Completion
- 2004-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flunarizine | Small molecule | 5 mg | — |
| Subject | Topiramate | Small molecule | 50 mg | — |